← Leaderboards
Brian D Lowes
University Of Colorado Denver
$1,893,454
Attributed
$3,019,165
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $751K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$3,019,165 · 7
By mechanism
P20$1,500,948 · 1
M01$864,817 · 5
K23$653,400 · 1
Top collaborators
- Peter Buttrick2 shared
- Jonathan David Port2 shared
- Christine C. Wu2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Robert W Schrier$16,805,433
- Lorna G. Moore$5,819,887
- Michael R. Bristow$7,111,960
- Matthew R Taylor$5,502,265
- Brian L Stauffer$5,871,842
Others in their field
Top investigators on “Heart Failure”
- Judith S Hochman · New York University School Of Medicine$120,321,606
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$51,947,333
- Lisa P Jacobson · Johns Hopkins University$45,397,923
- Walter N Kernan · Yale University$42,197,025
- Dalane W Kitzman · Wake Forest University$40,701,149
- David Couper · Univ Of North Carolina Chapel Hill$37,959,091
Research focus
Heart FailureHuman SubjectClinical ResearchHuman Therapy EvaluationGene ExpressionHeart Disorder ChemotherapyAce InhibitorsHemodynamicsHormone Regulation /Control MechanismHormone TherapyClinical TrialsThyroid HormonesHormone ReceptorInhibitor /AntagonistCombination ChemotherapyCardiotonic AgentsOral AdministrationEndothelinBiopsyDosageDrug Screening /EvaluationBeta Antiadrenergic AgentBaseHeart Function
Grant awards (23)
Using Molecular Pathology to Predict Response in Heart Failure$751,000
P20 · FY2011 · HL
Using Molecular Pathology to Predict Response in Heart Failure$749,948
P20 · FY2010 · HL · contact PI
Gene expression profiles in the failing human heart$130,680
K23 · FY2007 · HL · contact PI
Gene expression profiles in the failing human heart$130,680
K23 · FY2006 · HL · contact PI
Gene expression profiles in the failing human heart$130,680
K23 · FY2005 · HL
THYROID HORMONE AS A MODULATOR OF GENE EXPRESSION IN HEART FAILURE$3,146
M01 · FY2005 · RR
Gene expression profiles in the failing human heart$130,680
K23 · FY2004 · HL
Thyroid Hormone as a Modulator of Gene Expression$2,047
M01 · FY2004 · RR
Gene expression profiles in the failing human heart$130,680
K23 · FY2003 · HL
BMS 193884 VS PLACEBO IN HEART FAILURE$190,747
M01 · FY2002 · RR
THYROID HORMONE AND GENE EXPRESSION IN HEART FAILURE$190,747
M01 · FY2002 · RR
THYROID HORMONE AND GENE EXPRESSION IN HEART FAILURE$190,747
M01 · FY2001 · RR
BMS 193884 VS PLACEBO IN HEART FAILURE$190,747
M01 · FY2001 · RR
BMS 193884 VS PLACEBO IN HEART FAILURE$0
M01 · FY2001 · RR
THYROID HORMONE AND GENE EXPRESSION IN HEART FAILURE$0
M01 · FY2001 · RR
EVALUATION OF ONSET AND OFFSET HEMODYNAMIC EFFECTS OF OPC18790 IN HEART FAILURE$32,212
M01 · FY2000 · RR
BMS 193884 VS PLACEBO IN HEART FAILURE$32,212
M01 · FY2000 · RR
HEMODYNAMIC EFFECTS &SAFETY OF DUAL METALLOPROTEASE BMS186716 IN HEART FAILURE$32,212
M01 · FY2000 · RR
EVALUATION OF ONSET AND OFFSET HEMODYNAMIC EFFECTS OF OPC18790 IN HEART FAILURE$0
M01 · FY2000 · RR
BMS 193884 VS PLACEBO IN HEART FAILURE$0
M01 · FY2000 · RR
HEMODYNAMIC EFFECTS &SAFETY OF DUAL METALLOPROTEASE BMS186716 IN HEART FAILURE$0
M01 · FY2000 · RR
THYROID HORMONE AND GENE EXPRESSION IN HEART FAILURE$0
M01 · FY2000 · RR
THYROID HORMONE AND GENE EXPRESSION IN HEART FAILURE$0
M01 · FY2000 · RR